Aortic Endograft Global Market Report 2024

The aortic endograft market size has grown strongly in recent years. It will grow from $3.14 billion in 2023 to $3.35 billion in 2024 at a compound annual growth rate (CAGR) of 6.7%. The growth observed in the historic period can be attributed to various factors, including the expansion of medical tourism, a growing demand for aortic aneurysm management, an increasing number of cases related to aortic aneurysms, the technical success of endograft implantation procedures, and the rise in the number of hospitals.

The aortic endograft market size is expected to see strong growth in the next few years. It will grow to $4.08 billion in 2028 at a compound annual growth rate (CAGR) of 5.1%. The anticipated growth in the forecast period can be attributed to several factors, including the increasing prevalence of abdominal aortic aneurysms, a growing preference for minimally invasive endovascular procedures, a rising geriatric population, advancements in stent-graft materials and configurations, and the introduction of new stent-graft products. Major trends expected in the forecast period encompass the adoption of endovascular abdominal aortic aneurysm (AAA) repair devices, the effectiveness of unibody and non-unibody aortic stents, and ongoing product innovation.

The increasing prevalence of aortic aneurysms is anticipated to drive the growth of the aortic endograft market in the foreseeable future. Aortic aneurysms, characterized by abnormal dilation of the aorta, the body's largest artery, are effectively treated using aortic endografts, known for their minimally invasive nature compared to traditional open surgery. These devices, typically composed of fabric-covered metal or polymer, are introduced through a catheter, reinforcing weakened aortic walls and reducing the risk of rupture. Notably, in February 2023, data from the UK-based Government Digital Service revealed that approximately 274,800 men underwent screening, with 79% receiving conclusive results and the detection of 1,794 aneurysms between April 2021 and March 2022. This underscores the driving force of the growing prevalence of aortic aneurysms in fostering the expansion of the aortic endograft market.

Prominent companies operating in the aortic endograft market are actively pursuing innovative solutions to maintain a competitive advantage. One such advancement is the castor-branched aortic stent graft system, designed to address aortic and aortic arch issues with a minimally invasive approach, particularly in Stanford type B aortic dissection (TBAD) cases. For instance, in December 2021, Shanghai MicroPort Endovascular MedTech Group Co. Ltd., a China-based manufacturer specializing in aortic and peripheral vascular intervention devices, introduced the Castor Branched Aortic Stent-Graft System. Recognized as the world's first stent-graft device for simultaneous aortic and aortic arch repair through minimally invasive therapy, its unique unibody design adapts to diverse arch anatomies, ensuring secure and straightforward reconstruction of the left subclavian artery. This feature not only minimizes the risk of endoleaks but also promotes long-term stability, positioning it as an innovative solution in the aortic endograft market.

In April 2021, Endologix LLC, a prominent US-based medical devices company, finalized the acquisition of PQ Bypass Inc. for an undisclosed sum. This strategic move empowers Endologix to strengthen and broaden its presence in the treatment of abdominal aortic aneurysms, positioning it as a leader in pioneering technologies for addressing vascular disease. PQ Bypass Inc., also based in the US, specializes in medical devices, particularly aortic endografts.

Major companies operating in the aortic endograft market report are Cardinal Health Inc., Abbott Laboratories, Medtronic Plc, Becton, Dickinson and Company, Koninklijke Philips N.V., Boston Scientific Corporation, Terumo Corporation, W. L. Gore & Associates Inc., Cook Medical Inc., Merit Medical Systems Inc., Penumbra Inc., LifeTech Scientific Corporation, Altura Medical Inc., MicroVention Inc., MicroPort Scientific Corporation, CryoLife Inc., Cordis Corporation, Endologix LLC, Braile Biomédica Indústria Comércio e Representações Ltda., Nano Endoluminal S.A., Biomerics LLC, JOTEC GmbH, Lombard Medical Inc., Aptus Endosystems Inc., Lombardi SA, Cardiatis S.A., Endospan Ltd., Transcatheter Technologies GmbH.

North America was the largest region in the aortic endograft market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the aortic endograft market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the aortic endograft market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

An aortic endograft, also known as an endovascular stent graft, is a minimally invasive medical device designed to repair weakened areas of the aorta, the primary artery responsible for transporting blood from the heart to the rest of the body. This device serves as an alternative to traditional open surgery for treating aortic aneurysms.

The primary categories of aortic endografts include abdominal aortic grafts and thoracic aortic grafts. Abdominal aortic grafts are specifically implanted in the abdominal aorta to address aneurysms by reinforcing weakened arterial walls. These devices can be made from materials such as metallic endografts and polymeric endografts, and the procedures involved include open surgical repair and endovascular aneurysm repair (EVAR). Aortic endografts are commonly utilized in medical settings, including hospitals and ambulatory surgical centers.

The aortic endografts market research report is one of a series of new reports that provides aortic endografts market statistics, including aortic endografts industry global market size, regional shares, competitors with aortic endografts market share, detailed aortic endografts market segments, market trends, and opportunities, and any further data you may need to thrive in the aortic endografts industry. This aortic endografts market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The aortic endograft market consists of revenues earned by entities by training programs, educational services, maintenance, and support services. The market value includes the value of related goods sold by the service provider or included within the service offering. The aortic endograft market also includes sales of endoanchors and sealants. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.